Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294190 · ClinicalTrials.gov registry record · Phase 2
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
A Phase 2 study of Small-cell Lung Cancer and Carcinoma, Small Cell, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 13
- Study locations
NCT00294190: Completed Phase 2 study of Small-cell Lung Cancer and Carcinoma, Small Cell, sponsored by SCRI Development Innovations.
NCT00294190 is a Phase 2 study of Small-cell Lung Cancer and Carcinoma, Small Cell that has completed, run by SCRI Development Innovations. The registered enrollment target is 38 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00294190, a Phase 2 study of Small-cell Lung Cancer and Carcinoma, Small Cell, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 13
- Study locations
Study Summary
This proposed phase II trial will investigate weekly topotecan at a higher dose than was used in the previous trials in an attempt to achieve improved response rates and disease control without added toxicity. To help ameliorate the fatigue, planned rest weeks will be incorporated into the schedule. This trial will be the first clinical trial to evaluate a higher dose of weekly topotecan in the treatment of extensive-stage SCLC.
Conditions Studied
Interventions
- DRUG Topotecan
Study Locations (13)
Florida
- Florida Cancer Specialists - Fort Myers
- Watson Clinic Center for Cancer Care and Research - Lakeland
- Florida Hospital Cancer Institute - Orlando
Tennessee
- Chattanooga Oncology Hematology Associates - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Arkansas
- Northeast Arkansas Clinic - Jonesboro
Georgia
- Northeast Georgia Medical Center - Gainesville
Kentucky
- Consultants in Blood Disorders and Cancer - Louisville
Louisiana
- Hematology Oncology Life Center - Alexandria
Michigan
- Grand Rapids Clinical Oncology Program - Grand Rapids
Nebraska
- Methodist Cancer Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00294190 record still lists
NCT00294190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Topotecan is the first listed.
NCT00294190 lists 13 locations in 10 states (Florida, Tennessee, Arkansas).
Frequently Asked Questions
What is clinical trial NCT00294190 about?
NCT00294190 is a clinical study titled "Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer". This proposed phase II trial will investigate weekly topotecan at a higher dose than was used in the previous trials in an attempt to achieve improved response rates and disease control without added toxicity. To help ameliorate the fatigue, planned rest weeks will be incorporated into the schedule....
What is the current status of trial NCT00294190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2006-02. Estimated completion is 2009-07.
What conditions does trial NCT00294190 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Carcinoma, Small Cell.
What interventions are being tested in trial NCT00294190?
The interventions under investigation include: Topotecan (DRUG).
Who is sponsoring clinical trial NCT00294190?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00294190 being conducted?
This trial has 13 study locations across Arkansas, Florida, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00294190's enrollment target sits among peer trials
38 58th of 79 higher than 21 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia